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Background:  The development of new therapies for heart failure (HF) is a high priority. The endogenous natriuretic peptides (NPs) ANP, BNP 
and CNP mediate cardiac unloading, renal enhancing, vasoprotective and RAAS suppressing actions via the receptors guanylyl cyclase (GC)-A and 
GC-B, respectively. We engineered CD-NP as a novel NP that activates both GC-A and GC-B, with higher activity at GC-B so as to be less hypotensive 
than the GC-A agonists ANP and BNP. The cardiorenal and neurohumoral actions of CD-NP in HF patients are undefined. We hypothesized CD-NP 
will suppress RAAS via GC-A activation, unload the heart while maintaining blood pressure (BP) taking advantage of GC-B activation and preserving 
glomerular filtration rate (GFR) secondary to both GC-A and GC-B.
Methods:  Subjects with stable, chronic HF (ejection fraction ≤40%) were enrolled in a randomized, double-blind, placebo-controlled, proof-of-
concept study. Randomization was to either placebo (n=5) or CD-NP (20 ng/kg/min; n=9; Nile Therapeutics) for 4 hours. On the study day, patients 
received their usual cardiac medications except diuretics. GFR was measured by iothalamate. BP, aldosterone and ANP were also assessed, the latter 
to assess cardiac unloading. After equilibration, a 60’ baseline clearance (C1) was done, followed by two 120’ clearances (C2 and C3, respectively) 
with CD-NP or placebo, and finally a 120’ post-infusion clearance (C4). Changes from baseline were compared between groups. p-values are CD-NP 
vs. placebo.
Results:  CD-NP increased cGMP, the second messenger of the NPs, in C2 and C3 (p<0.05). CD-NP as compared to placebo did not change BP or 
heart rate. GFR (p=0.04) increased with CD-NP in C2. CD-NP decreased aldosterone in C3 (p=0.01) and tended to do so in C2 (p=0.054). CD-NP 
decreased ANP in C4, consistent with greater cardiac unloading.
Conclusions:  In a proof-of-principle placebo-controlled study in HF, CD-NP, a dual agonist for GC-A and GC-B with GC-B>GC-A activity, activated 
cGMP, maintained BP, and showed aldosterone suppressing, cardiac unloading, and renal preserving actions.
